Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Hosted on MSN20h
Equifax (EFX) Earnings Expected to Grow: Should You Buy?Wall Street expects a year-over-year increase in earnings on higher revenues when Equifax (EFX) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...
Zacks.com on MSN1d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
GlobalData on MSN2d
Akero’s cirrhosis treatment shows promise in Phase IIb studyIn subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.
Morgan Stanley lowered the firm’s price target on Equifax (EFX) to $316 from $320 and keeps an Overweight rating on the shares. While the firm ...
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback